Navy to Test Vical Vaccine Combo

11/6/08

San Diego-based biotech firm Vical (NASDAQ:VICL) reports that the Naval Medical Research Center plans to conduct tests and early clinical trials of a DNA vaccine formulated with its vaccine adjuvant (Vaxfectin) with a needle-free injection system for potentially lethal dengue infections. Vical plans to manufacture the vaccine and adjuvant under a $1.3 million contract, and the study is expected to take place at Walter Reed Army Institute of Research.

By posting a comment, you agree to our terms and conditions.